Inclusion Criteria:

          -  18 years of age or older

          -  Biopsy-proven (consisting of ≥ 12 tissue cores) adenocarcinoma of the prostate with
             cancer present in at least one biopsy core (TRUS or/and mpMRI/TRUS fusion), Gleason
             score (3+3) or predominant Gleason pattern 3 (3+4), ≤ 33% of biopsy cores, and ≤50%
             involvement of any biopsy core (Participant meets all criteria for Active Surveillance
             as determined by MD)

          -  Willing to start or continue on active surveillance

          -  Screening serum PSA <10 ng/mL or PSAD <0.15 ng/mL/g

          -  No other prior treatment for PCa, including focal therapy

          -  ECOG performance status 0-1

          -  No history of renal or hepatic disease, including history of hepatitis B and C

          -  Meet hematological eligibility parameters (Neutrophil count ≥ 1,200/mm3 (≥1.2 k/μL),
             Stable platelet count ≥ 75,000/mm3 (≥ 75k/μL) Hepatic and renal function eligibility
             parameters, serum total Bilirubin ≤ULN (ULN: 1.2 mg/dl) (or ≤3.0 mg/dL for patients
             with Gilbert's syndrome), AST or ALT <1.5x ULN and Serum creatinine ≤1.5 x ULN

          -  Willing to abstain from consumption of any supplements containing GTC

          -  Willing to restrict tea consumption to less than three (3) servings of hot tea or
             three (3) servings of iced tea per week

          -  Willing to discontinue current vitamin/mineral supplement use and use one provided by
             study

          -  Willing to take study agent or placebo at the dose specified with meals.

        Exclusion Criteria:

          -  Have had prior treatment for PCa by surgery, irradiation, local ablative (i.e.,
             cryosurgery or high-intensity focused ultrasound), or androgen-deprivation therapy)

          -  Men treated with 5- alpha-reductase inhibitors (e.g., finasteride, dutasteride)

          -  Participants who have PCa with distant metastases

          -  Participants who have been treated with: hormone therapy, immunotherapy, chemotherapy
             and/or radiation, for any malignancies within the past 2 years

          -  Participants may not be receiving any other investigational agents

          -  History of allergic reactions attributed to tea or compounds of similar chemical or
             biologic composition to green tea extracts.